Psyence Biomedical Ltd. has entered a significant partnership with Benuvia Operations, LLC, to establish U.S. manufacturing of pharmaceutical-grade ibogaine. This collaboration is set to enhance Psyence's production capabilities and regulatory compliance, marking a pivotal step in the company's strategy to develop ibogaine-based therapies.
The announcement, made on October 5, 2026, indicates that Psyence's wholly-owned Texas subsidiary, Texas Ibogaine Research Corporation (TIRC), will work with Benuvia, which operates a DEA-registered facility in Round Rock, Texas. This facility is equipped for the development and commercial-scale production of controlled substances, including ibogaine.
Background
Psyence Biomedical Ltd. is a biopharmaceutical company listed on Nasdaq under the ticker symbols PBM and PBMWW. The company specializes in neuroplastogen-based therapeutics and is focused on developing nature-derived treatments for mental health disorders. Psyence operates through its subsidiary, TIRC, and is committed to addressing unmet mental health needs through evidence-based approaches.
What the Filing Says
The filing states, "On October 5, 2026, the Company issued a press release titled 'Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine.'" This partnership aims to create a manufacturing pathway for pharmaceutical-grade ibogaine as TIRC advances its planned U.S. development program.
Impact
This partnership is expected to affect various stakeholders in the pharmaceutical preparations industry. With Benuvia's established manufacturing capabilities and Psyence's planned exclusive U.S. access to PsyLabs' pharmaceutical-grade ibogaine, the collaboration could reshape the landscape of ibogaine production and its availability for clinical use.
What's Next
The filing indicates that a definitive agreement between Psyence and PsyLabs is to be concluded on or before November 30, 2026. This agreement will supersede the previously announced binding term sheet and is crucial for advancing the manufacturing and distribution of ibogaine.